Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis
Philip Gorwood(Inserm), Pierre‐Michel Llorca(Institut Pascal), Guillaume Vaïva(Inserm), Philippe Courtet(Fondation FondaMental), Emmanuelle Corruble(Inserm), Franck Baylé(Centre Hospitalier Sainte-Anne)
Cited by 31
Related Papers
How mental health care should change as a consequence of the COVID-19 pandemic
|The Lancet Psychiatry|2020|1.9k
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
|Nature Reviews Drug Discovery|2012|1.3k
The consequences of the COVID-19 pandemic on mental health and implications for clinical practice
|European Psychiatry|2020|1.2k